演題詳細

ポスター / Poster

ポスター 6 (Poster 6) :AML:発症・治療・その他

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
安部 明弘 (Akihiro Abe):1
1:藤田保健衛生大学 血液内科
 
前へ戻る

AML with t(8;18;12;21)(q22;q21;p13;q22) and FLT3/ITD mutation conducted cord blood transplantation

演題番号 : PS-1-38

新井 宏典 (Hironori Arai):1、青墳 信之 (Nobuyuki Aotsuka):1、山口 真璃子 (Mariko Yamaguchi):1、宇津 欣和 (Yoshikazu Utsu):1、増田 真一 (Shinichi Masuda):1、松浦 康弘 (Yasuhiro Matsuura):1、脇田 久 (Hisashi Wakita):1

1:Depertment of Hematology and Oncology, Japanese Red Cross Narita Hospital

 

[Case] A 36-year-old woman seen was diagnosed as AML with chromosomal and genetic abnormalities such as t(8;21;12;21)(q22;q21;p13;q22) and FLT3/ITD mutation in October 2012. She received standard induction therapy and achieved hematological complete response(hCR), followed by two courses of high-dose cytarabine consolidation therapy. Mainly because she had FLT3/ITD mutation which was one of poor prognostic factors, we thought she needed allogeneic stem cell transplantation (allo-SCT). Since she could get a donor from neither her sibling nor unrelated bone marrow donors, she received cord blood transplantation after second consolidation therapy in the first hCR. The progress after the transplantation was satisfactory without any serious problems. She was discharged after 60 days and started receiving regular outpatient treatment. [Discussion] Patients who develop AML with t(8;21) are likely to have good progress, therefore allo-SCT is not always necessary. However, reports of AML with chromosomal 4 way translocation are so few that we can't estimate the influence on its prognosis. AML with FLT3/ITD mutation is generally said to have poor prognosis, which is also true in CBF-AML. To our knowledge, patients who achieved over 3-log MRD reduction after first consolidation therapy are likely to have a good progress. Our case also met that requirement. Taking these factors into consideration, we finally decided to conduct allo-SCT. Since factors that influence on the prognosis of AML are recently increasing, we have to update our knowledge continuously.

前へ戻る